Bioprocessing & Manufacturing Conference 2017 logo

Optimize early formulation through to clinical manufacturing, by embracing new techniques and technologies

ABOUT THE
BIOPROCESSING AND MANUFACTURING CONFERENCE

 

With new vaccine formulations and technology platforms, vaccine developers need to have the right processes in place to manufacture them during clinical trials and at commercial scale.

Use this opportunity to meet with the manufacture and bioprocessing leads who need services for all of the latest manufacturing challenges, from formulating and manufacturing adjuvants, mRNA platforms, VLPs and viral vectors, to technology transfer and continuous manufacturing.

SCROLL DOWN FOR THE 2017 AGENDA

 

2017 AGENDA

Bioprocessing & Manufacture, Tuesday 11 April 2017

Bioprocessing & Manufacture
09:00

Chair’s opening remarks

   
Dr Derek O'Hagan
Bioprocessing & Manufacture
09:10

Designing and building the next generation of vaccine adjuvants

  • Key attributes necessary to generate well characterized adjuvant formulations
  • Vaccine/Adjuvant Delivery Issues & Systems
Mr Manmohan Singh
Bioprocessing & Manufacture
09:40

Rational design of Vaccine Formulations: Defining your formulation strategy for vaccines

  • Development of formulation process and transfer to GMP department
  • Support to regulatory filing
  • High throughput formulation methodologies to de-risk manufacturing issues
Dr Anass Jawhari
Bioprocessing & Manufacture
10:10

How process parameters impact your final vaccine formulation and stability

  • Vaccine design & formulation
  • Molecular approaches to vaccine design
    Vaccine immunology/immunogenicity studies for better characterization and prediction methods
  • Vaccine stability monitoring methods
Senior representative, Calixar
Dr Anass Jawhari, Chief Scientific Officer and Director of R and D, Calixar
Mr Chris Kemp
Bioprocessing & Manufacture
10:25

Monitoring VLP production using The ViroCyt 3100 Virus Counter

10:40

Networking coffee break

Devon DuBose
Bioprocessing & Manufacture
11:40

Dry powder vaccine stabilization and delivery by spray drying

  • Methods and considerations for Spray dried macromolecules
  • Different Delivery Routes and their application to spray drying
  • Enteric Capsules for oral delivery and rapid pre-clinical development
  • Case Studies
Bioprocessing & Manufacture
12:10

How to determine and deploy QbD and critical attributes for successful vaccine development

  • Critical Quality Attributes -identification and acceptance ranges
  • Analytical Control Strategy
  • Process Understanding
  • The added value of applying QbD to vaccines
Dr Joseph Joyce
Bioprocessing & Manufacture
12:40

Challenges in the development and scale-up of an attenuated live virus vaccine candidates

13:10

Networking Lunch & Poster Session

Mr Regis Gervier
Bioprocessing & Manufacture
14:40

Innovation and challenges for development and industrialization of vaccines

  • Incorporating new technologies
  • Department covering New Biological Entities Process industrialization (Ph III and ownwards) Process and Analytics Life Cycle Management, Manufacturing Support
Bioprocessing & Manufacture
15:10

Challenges and considerations in developing nucleic based vaccines – with the rise of DNA and RNA vaccines, is the upscale and manufacturing approaches different?

Mr Glen Zimmermann
Bioprocessing & Manufacture
15:40

Solutions for intradermal administration & clinical experience with the MicronJet600R

16:10

Networking coffee break

Bioprocessing & Manufacture
16:40

Bioreactor needs for the developing world: Vaccine self-sufficiency and pandemic outbreaks

Ms Michele D'Alessandro
Bioprocessing & Manufacture
17:10

IT innovations and their impact on vaccine bioprocessing and manufacturing development

  • Having the ability to interrogate manufacturing data
  • Bringing highly structured data and highly unstructured data together for analysis and aggregation
  • How to analyse production processes that are inherently variable
  • Lessons learned and progress made
Dr Daniel Vellom
Bioprocessing & Manufacture
17:40

Continuous manufacturing: A reality only for bigger players?

  • Capital efficiency for continuous manufacturing techniques and facilities
  • Does the future include smaller players and CMOs?
  • Benefits to vaccine manufacturing and other biologics as we increasingly combine approaches
Bioprocessing & Manufacture
18:10

Novel pathways to robust and cost-effective vaccine manufacturing

18:40

Chair’s closing remarks and close of congress day 2

18:45

Networking Drinks & Party

last published: 12/Jan/17 13:37

 

Bioprocessing & Manufacture, Wednesday 12 April 2017

Professor Fikri Avci
Bioprocessing & Manufacture
09:10

Conjugate vaccine discovery and in vitro assays

  • Presentation focus on structure function relationship
Dr Michael Kowarik
Bioprocessing & Manufacture
09:40

Bioconjugation technology for the next generation of conjugate vaccines: Recent improvements, CQAs, and analytics method development

 
  • Technology advantages and opportunities
  • Focus on development and characterization of bioconjugate vaccine candidates
  • Discussion of CQAs based on preclinical and clinical POC data
Dr Michael Kowarik
Bioprocessing & Manufacture
09:40

Bioconjugation technology for the next generation of conjugate vaccines: Recent improvements, CQAs, and analytics method development

  • Technology advantages and opportunities
  • Focus on development and characterization of bioconjugate vaccine candidates
  • Discussion of CQAs based on preclinical and clinical POC data
Dr Dicky Abraham
Bioprocessing & Manufacture
10:10

Process Development, Scale-up and COG of conjugate vaccines

 
  • Presentation on Scale-up commercial manufacturing and challenges
  • Impact on COGS
  • Incl. Classical and modern  conjugation reactions
10:40

Networking coffee break

Matt Roberge
Bioprocessing & Manufacture
11:30

Global and localized drug product supply chain

 
  • Modular drug product production
Dr Willie Vann
Bioprocessing & Manufacture
12:00

Regulatory perspective on new technologies including disposable flexible systems and upcoming trends

12:30

Networking Lunch & Poster Session

Dr Alan R. Hinman
13:40

The eradication of Polio: Have we succeeded?


-    Measuring and monitoring the success of eradication
-    End game and strategic plan
-    What’s next? Can we eradicate measles?
 
Professor Robert Daum
14:10

A call for greater consideration for the role of vaccines in national strategies to combat antibiotic-resistant bacteria


-    Recommendations from the National Vaccine Advisory Committee
-    Use of vaccines to prevent the infections that could or have developed AMR to antibiotics, in adjunction to antibiotic stewardship
-    Examples in Haemophilus influenza, Streptococcus, Staphylococcus aureus

 
Dr Danilo Casimiro
14:40

Panel: How much efficacy is enough? What are the implications of a vaccine no longer being a replacement technology but a companion technology?


-    The concept of partially protected vaccines like malaria, TB, NTDs where the clinical efficacy is no longer 85/90% but closer to 40% 
-    Future of vaccine development 
-    The combining drivers of technology and emerging diseases

More panelists to be announced shortly
15:30

Chair’s closing remarks and close of congress

last published: 12/Jan/17 13:37

 

Sign up for event updates

WHO ATTENDS?

  • Pharma
  • Biotech
  • National and International Government
  • Academics And Research Institutions ​

JOB TITLES

  • Head of Bioprocessing
  • Head of Manufacturing
  • Head of Formulation
  • Head of Biopharmaceutical Development
  • Head of Upstream / Downstream Process
  • Head of R&D
  • Head of Procurement
  • Head of CMC​ ​

 

 

WHO SPONSORS?

  • CMOs
  • Fill / Finish
  • Finished Dosage
  • Platform Technology Providers
  • Big Pharma
  • Biotech